Evidence map›Paper›PMID 35719352›Full record

ArticleFrontiers in cellular and infection microbiology2022

A Microbiota-Dependent Response to Anticancer Treatment in an

Claire Amaris Hobson, Lucile Vigué, Mélanie Magnan, Benoit Chassaing, Sabrine Naimi, Benoit Gachet, Pauline Claraz, Thomas Storme, Stephane Bonacorsi, Olivier Tenaillon and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Gut · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Claire Amaris HobsonIAME, UMR 1137, INSERM, Université de Paris, AP-HP, Paris, France.
Lucile ViguéIAME, UMR 1137, INSERM, Université de Paris, AP-HP, Paris, France.
Mélanie MagnanIAME, UMR 1137, INSERM, Université de Paris, AP-HP, Paris, France.
Benoit ChassaingINSERM U1016, team "Mucosal microbiota in chronic inflammatory diseases", CNRS UMR 8104, Université de Paris, Paris, France.
Sabrine NaimiINSERM U1016, team "Mucosal microbiota in chronic inflammatory diseases", CNRS UMR 8104, Université de Paris, Paris, France.
Benoit GachetIAME, UMR 1137, INSERM, Université de Paris, AP-HP, Paris, France.
Pauline ClarazService de pharmacie-Hôpital Robert Debré, DMU PRISME, AP-HP. Nord, Paris, France.
Thomas StormeService de pharmacie-Hôpital Robert Debré, DMU PRISME, AP-HP. Nord, Paris, France.
Stephane BonacorsiIAME, UMR 1137, INSERM, Université de Paris, AP-HP, Paris, France.
Olivier TenaillonIAME, UMR 1137, INSERM, Université de Paris, AP-HP, Paris, France.
André BirgyIAME, UMR 1137, INSERM, Université de Paris, AP-HP, Paris, France.
Inserm · FRUniversité Paris Cité · FRCentre National de la Recherche Scientifique · FRHôpital Robert-Debré · FRAssistance Publique – Hôpitaux de Paris · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Anticancer drug efficacy is linked to the gut microbiota's composition, and there is a dire need to better understand these interactions for personalized medicine. Methods: The MBRA is a single-stage continuous-flow culture model, hosted in an anaerobic chamber. We evaluated the effect of a 5-day treatment with hydroxycarbamide or daunorubicine on the fecal bacterial communities of two healthy donors. 16S microbiome profiling allowed analysis of microbial richness, diversity, and taxonomic changes. Results: In this host-free setting, anticancer drugs diversely affect gut microbiota composition. Daunorubicin was associated with significant changes in alpha- and beta-diversity as well as in the ratio of Firmicutes/Bacteroidetes in a donor-dependent manner. The impact of hydroxycarbamide on microbiota composition was not significant. Conclusion: We demonstrated, for the first time, the impact of anticancer drugs on human microbiota composition, in a donor- and molecule-dependent manner in an

Indexed as

Gastrointestinal MicrobiomeMicrobiotaDaunorubicinFecesHumansPilot ProjectsRNA, Ribosomal, 16SDaunorubicinRNA, Ribosomal, 16Santicancer treatment and bacteriadaunorubicingut microbiotahydroxycarbamidein vitro microbiota modelMBRA

Identifiers

PMID35719352
PMCPMC9198576
OpenAlexW4281667301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.